Literature DB >> 32508005

The Successful Return-To-Work Questionnaire for Cancer Survivors (I-RTW_CS): Development, Validity and Reproducibility.

Michiel A Greidanus1, Angela G E M de Boer2, Angelique E de Rijk3, Sonja Brouwers2, Theo M de Reijke4, Marie José Kersten5, Jean H G Klinkenbijl6,7, Roy I Lalisang8, Robert Lindeboom9, Patricia J Zondervan4, Monique H W Frings-Dresen2, Sietske J Tamminga2.   

Abstract

BACKGROUND: Cancer survivors' perspectives on a successful return to work (RTW) may not be captured in the common measure of RTW, namely time until RTW.
OBJECTIVE: The purpose of this study was therefore to develop an RTW outcome measure that reflects employed cancer survivors' perspectives, with items that could be influenced by an employer, i.e. the Successful Return-To-Work questionnaire for Cancer Survivors (I-RTW_CS), and to assess its construct validity and reproducibility.
METHODS: First, three focus groups with cancer survivors (n = 14) were organized to generate issues that may constitute successful RTW. Second, a two-round Delphi study among 108 cancer survivors was conducted to select the most important issues. Construct validity of the I-RTW_CS was assessed using correlations with a single-item measure of successful RTW and the Quality of Working Life Questionnaire for Cancer Survivors (QWLQ-CS; n = 57). Reproducibility (test-retest reliability) was assessed using the intraclass correlation coefficient (ICC; n = 50).
RESULTS: Forty-eight issues were generated, of which seven were included: 'enjoyment in work'; 'work without affecting health'; 'confidence of employer without assumptions about work ability'; 'open communication with employer'; 'feeling welcome at work'; 'good work-life balance'; and 'joint satisfaction with the situation (employer and cancer survivor)'. Correlations with single-item successful RTW and QWLQ-CS were 0.58 and 0.85, respectively. The reproducibility showed an ICC of 0.72.
CONCLUSIONS: The I-RTW_CS provides an RTW outcome measure that includes cancer survivors' perspectives and weights its items on an individual basis, allowing a more meaningful evaluation of cancer survivors' RTW. This study provides preliminary evidence for its construct validity and reproducibility.

Entities:  

Mesh:

Year:  2020        PMID: 32508005      PMCID: PMC7478947          DOI: 10.1007/s40271-020-00427-6

Source DB:  PubMed          Journal:  Patient        ISSN: 1178-1653            Impact factor:   3.883


  32 in total

1.  A critical appraisal of evidence-based medicine: some ethical considerations.

Authors:  M Gupta
Journal:  J Eval Clin Pract       Date:  2003-05       Impact factor: 2.431

2.  Success in the workplace following traumatic brain injury: are we evaluating what is most important?

Authors:  William Levack; Kath McPherson; Harry McNaughton
Journal:  Disabil Rehabil       Date:  2004-03-04       Impact factor: 3.033

Review 3.  The effect of cancer treatment on cognitive function.

Authors:  Arash Asher; Jamie S Myers
Journal:  Clin Adv Hematol Oncol       Date:  2015-07

Review 4.  The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30.

Authors:  M T King
Journal:  Qual Life Res       Date:  1996-12       Impact factor: 4.147

Review 5.  Interventions to enhance return-to-work for cancer patients.

Authors:  Angela G E M de Boer; Tyna K Taskila; Sietske J Tamminga; Michael Feuerstein; Monique H W Frings-Dresen; Jos H Verbeek
Journal:  Cochrane Database Syst Rev       Date:  2015-09-25

6.  Towards a new definition of return-to-work outcomes in common mental disorders from a multi-stakeholder perspective.

Authors:  Hiske L Hees; Karen Nieuwenhuijsen; Maarten W J Koeter; Ute Bültmann; Aart H Schene
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

7.  Employment and social benefits up to 10 years after breast cancer diagnosis: a population-based study.

Authors:  C H Paalman; F E van Leeuwen; N K Aaronson; A G E M de Boer; L van de Poll-Franse; H S A Oldenburg; M Schaapveld
Journal:  Br J Cancer       Date:  2016-01-12       Impact factor: 7.640

8.  The quality of working life questionnaire for cancer survivors (QWLQ-CS): factorial structure, internal consistency, construct validity and reproducibility.

Authors:  Merel de Jong; Sietske J Tamminga; Robert J J van Es; Monique H W Frings-Dresen; Angela G E M de Boer
Journal:  BMC Cancer       Date:  2018-01-10       Impact factor: 4.430

9.  The MiLES intervention targeting employers to promote successful return to work of employees with cancer: design of a pilot randomised controlled trial.

Authors:  Michiel A Greidanus; Angela G E M de Boer; Angelique E de Rijk; Monique H W Frings-Dresen; Sietske J Tamminga
Journal:  Trials       Date:  2020-04-28       Impact factor: 2.279

10.  Supporting employers to enhance the return to work of cancer survivors: development of a web-based intervention (MiLES intervention).

Authors:  M A Greidanus; A G E M de Boer; C M Tiedtke; M H W Frings-Dresen; A E de Rijk; S J Tamminga
Journal:  J Cancer Surviv       Date:  2020-01-14       Impact factor: 4.442

View more
  4 in total

Review 1.  The Cross-Country Comparison Model for Labor Participation (CCC Model for LP) of Persons with Chronic Diseases.

Authors:  Angelique de Rijk; Karina Carrasco-Negüe; Inge Houkes
Journal:  J Occup Rehabil       Date:  2022-06-20

2.  Supporting the Return to Work of Breast Cancer Survivors: From a Theoretical to a Clinical Perspective.

Authors:  Bertrand Porro; Mario Campone; Philippe Moreau; Yves Roquelaure
Journal:  Int J Environ Res Public Health       Date:  2022-04-22       Impact factor: 4.614

3.  Regarding: Humayra Rashid et al. (2020) Returning to work in lung cancer survivors-a multi-center cross-sectional study in Germany. Supp Care Cancer; Published 19 November 2020.

Authors:  Masamitsu Kobayashi; Jun Kako; Kohei Kajiwara; Ayako Ogata
Journal:  Support Care Cancer       Date:  2021-02-03       Impact factor: 3.603

4.  A randomised feasibility trial of an employer-based intervention for enhancing successful return to work of cancer survivors (MiLES intervention).

Authors:  M A Greidanus; A E de Rijk; A G E M de Boer; M E M M Bos; P W Plaisier; R M Smeenk; M H W Frings-Dresen; S J Tamminga
Journal:  BMC Public Health       Date:  2021-07-21       Impact factor: 3.295

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.